Facebook
Twitter
LinkedIn
ForwardThe Future of Systemic Lupus Erythematosus Diagnosis and Treatment - Socioeconomic Determinants in Lupus
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that is difficult to diagnose and challenging to treat. It can involve multiple organ systems, leading to significant reduction in both the quality of life and overall lifespan of affected individuals. Despite published criteria designed for research studies, it remains difficult to recognize patients in practice, especially early in the course of disease. The management of patients is hampered by the lack of modern treatment guidelines and only a few therapies specifically developed for lupus. This internet activity, designed for physicians and researchers, consists of 8 sessions that bring SLE experts together to explain, via didactic lecture and case studies, current information on the cause of this mystifying illness, identify the best way to identify patients in practice, and describe the current and future therapies for lupus patients. Eight individual sessions are provided to offer specific SLE management strategies. 'Socioeconomic Determinants in Lupus' is session 1 of this 8 part program
Method of Participation
This continuing medical education enduring material is in a video format.
To receive a maximum of 1.25 AMA PRA Category 1 Credit(s)™ and ABIM MOC points, you should:
- View the videos in this enduring material.
- Complete the posttest (A passing score of 75% is required).
- Complete and submit the CME evaluation form.
The estimated time to complete this activity, including review of the materials, is 1.25 hours.
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Mozilla Firefox, and Google Chrome.
If you have questions about the participation process, please e-mail the UT Southwestern Medical Center, [email protected].
Target Audience
THIS ACTIVITY IS INTENDED FOR PROVIDERS IN THE SPECIALTIES OF:
- Rheumatology
- Nephrology
Learning Objectives
- Describe the current knowledge of the pathophysiology of lupus.
- Identify appropriate criteria and studies to accurately diagnose lupus.
- Select the most appropriate therapy options for lupus patients, taking into consideration differing organ-specific manifestations of the condition, such as lupus nephritis.
- Identify opportunities to advance research in lupus.
- Describe optimal treatment protocols for lupus nephritis.
Course Directors
David Karp, M.D., Ph.D.
Chief, Division of Rheumatic Diseases
UT Southwestern Medical Center
Kathryn Dao, M.D.
Associate Professor - Department of Internal Medicine, Division of Rheumatology
UT Southwestern Medical Center
Disclosure of Financial Relationships
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of any ineligible company, and promote improvements or quality in healthcare. In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).
The following is a listing of all individuals that contributed to the educational content of this activity and any reported financial relationships within the last 24 months:
NAME | ROLE | RELATIONSHIP | COMPANY |
|---|---|---|---|
Bonnie Bermas, M.D. | Peer Reviewer | None | N/A |
Ashira D. Blazer, M.D., MSCI | Speaker | Independent Contractor | GSK |
Kathryn Dao, M.D. | Course Director | Independent Contractor | Bristol Myers Squibb |
Lesley Davila, M.D. | Moderator | None | N/A |
Candace Feldman, M.D., MPH, Sc.D. | Speaker | Grant or Contract | Pfizer Pharmaceuticals |
David Karp, M.D., Ph.D. | Course Director | Grant or Contract | Bristol-Myers Squibb |
Educational Grants
The University of Texas Southwestern Medical Center gratefully acknowledges educational grants from the following companies in support of this CME activity: Aurinia Pharmaceuticals
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas Southwestern Medical Center designates this internet enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Available Credit
- 1.25 AMA
- 1.25 Attendance
Price
Registration
To register:
- "Login" to your existing account or create an account in EthosCE, online learning management system, by selecting the "create an account" link.
- Return to this course page and select the "Take Course" button.
- Registration will be completed.
Required Hardware/software
Activities will run on desktop or mobile device using the most recent version of common browsers, including Internet Explorer, Safari, Google Chrome or Mozilla Firefox.